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Abstract
Although Anaplastic Large Cell Lymphomas (ALCL) carrying Anaplastic Lymphoma Kinase 
(ALK) have a relatively good prognosis, aggressive forms exist. We have identified a novel 
translocation, causing the fusion of the TRAF1 and ALK genes, in one patient who presented with 
a leukemic ALK+ ALCL (ALCL-11). To uncover the mechanisms leading to high-grade ALCL, 
we developed a human Patient Derived Tumorgraft (hPDT) line. Molecular characterization of 
primary and PDT cells demonstrated the activation of ALK and of NFkB pathways. Genomic 
studies of ALCL-11 showed the TP53 loss and the in vivo subclonal expansion of lymphoma cells 
lacking PRDM1/Blimp-1 and with c-MYC gene amplification. The treatment with proteasome 
inhibitors of TRAF1-ALK cells led to down-regulation of p50/p52 and lymphoma growth 
inhibition. Moreover a NFkB gene set classifier stratified ALCL in distinct subsets with different 
clinical outcome. Moreover, a selective ALK inhibitor (CEP28122) resulted in a significant 
clinical response of hPDT mice, but the disease could not be eradicated.
These data indicate that the activation of NFkB signaling contributes to the neoplastic phenotype 
of TRAF1-ALK ALCL. ALCL hPDTs are invaluable to validate the role of druggable molecules, 
predict therapeutic responses and are helpful tools for the implementation of patient specific 
therapies.
Keywords
anaplastic large cell lymphoma (ALCL); Patient Derived Tumorgraft (PDT); Tyrosine kinase 
fusion proteins; personalized medicine; targeted therapy
INTRODUCTION
Anaplastic Large Cell Lymphomas (ALCL) are a distinct subset of mature T cell lymphoma 
and they can be subclassified based on the presence chromosomal translocations affecting 
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the Anaplastic Lymphoma Kinase (ALK) gene {Falini, 2009 #737; Swerdlow SH, 2008 
#1092}. In the 2008 revised WHO classification, ALK+ ALCL and cutaneous ALCL 
received distinct designations, while ALK- ALCL remained as a provisional entity in 
anticipation of additional data {Swerdlow SH, 2008 #1092}.
De novo ALK+ ALCL are clinically aggressive lymphomas, most frequently occurring in 
the first 3 decades of life, with a stage III–IV disease, systemic symptoms, and extranodal 
involvement (60%) and a typical male predominance {Savage, 2008 #1044},{Schmitz, 2010 
#1194}. Although the long-term clinical outcome for the majority of ALK+ ALCL patients 
is relatively favorable {Savage, 2008 #1044;Schmitz, 2010 #1194}, some patients can have a 
highly aggressive disease. Clinical development can include rapid nodal dissemination, 
extranodal involvement or even frank leukemic presentation {Monaco, 2007 #939;Liang, 
2013 #1195}. Moreover, 20–30% of ALK+ ALCL patients relapse and eventually require 
high dose chemotherapies and bone marrow transplantation {Savage, 2008 #1044;Schmitz, 
2010 #1194;Ferreri, 2012 #1193}.
The majority of ALK+ ALCL cases carry the t(2;5)(p23;q35) translocation, which fuses the 
3’ portion of the ALK into the nucleophosmin (NPM) gene. As a result of this translocation, 
affected cells display ectopic expression of the NPM-ALK fusion protein within the 
cytoplasm and nucleus. Approximately 20% of cases of ALK+ ALCL, however, exhibit 
different ALK fusions with a cytoplasmic localization {Barreca, 2011 #618}. The N-
terminus regions of all ALK chimera encode unique dimerization domains. These are critical 
for the constitutive activation of the kinases and required for ALK-mediated transformation. 
It is believed that ALK partners do not contribute otherwise to ALK lymphomagenesis. One 
notable exception has been identified in the TFG-ALK fusion, in which the TFG region can 
interact with NEMO and TANK leading to the NFkB activation {Miranda, 2006 #1197}.
ALK+ ALCL have more often a stable karyotypes {Boi, 2013 #1207}, supporting the 
hypothesis that they are highly addicted to ALK signaling and may not require multiple and 
synergizing alterations. Conversely, aggressive ALK+ cases have a large spectrum of 
chromosomal defects, frequently involving chromosome 8q, suggesting that the deregulated 
expression of MYC might leads to unfavorable clinical outcome {Grewal, 2007 
#790;Monaco, 2007 #939;Liang, 2013 #1195;Moritake, 2011 #941}.
Patient Derived Tumorgraft (PDT) in heavily immuno-compromised animals [i.e. NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice] are a valuable instrument to study human cancers 
{Shultz, 2012 #1058}. These mice display a high rate of engraftment {Quintana, 2008 
#1010} and provide a host environment capable to sustain the survival of neoplastic as well 
as normal human elements {Shultz, 2012 #1058}. The expansion of primary tumor cells 
provides abundant pathological tissues and the opportunity to test ad hoc protocols in a 
reasonable time-frame {Tentler, 2012 #1110}. Lastly, PDT enable the discovery of genetic 
lesions, which can be targeted by specific compounds {Garber, 2009 #1180} in ad hoc 
preclinical therapeutic protocols {Vilas-Zornoza, 2012 #1259;Cheng, 2011 #666;Rubio-
Viqueira, 2006 #1034}.
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Here, we have studied the tumorigenic properties of a novel TRAF1-ALK chimera 
{Feldman, 2013 #1226;Tabbo’, 2013 #1328}, which can elicit the inappropriate activation of 
ALK and NFkB pathways. Multiple genomic defects (loss of TP53, and Blimp1 and MYC 
amplification) were associated to a leukemic and chemo-resistant TRAF1-ALK ALCL 
patient. Notably, the usage of a specific ALK inhibitor could prolong the survival of ALCL 
PDT bearing mice, but was unable to eradicate the disease. Overall, PDT models represent a 
novel tool to validate therapeutic protocols and to predict clinical responses, particularly in 
the setting of refractory patients.
MATERIALS AND METHODS
Patients Selection and immunohistochemistry
Fresh and/or viable cryopreserved samples from primary ALCL were obtained at the time of 
diagnosis, before treatment, or at relapse after chemotherapy from the Universities of 
Perugia, Turin and Leuven. Diagnoses were assigned according to the WHO classification 
by at least two experienced pathologists. Informed consents were obtained following the 
recommendations of local ethical committees. Representative formalin-fixed tumor sections 
and/or tissue microarrays (TMAs) were processed for immunohistochemical (IHC) analyses 
on a semi-automated stainer {Piva, 2010 #8623}. List of the antibodies and staining 
conditions are provided in Supplemental Table S1.
Fluorescence in situ hybridization analysis
Cytogenetic and fluorescence in situ hybridization (FISH) followed routine methods. 
Interphase FISH was performed on FFPE sections. FFPE sections were pretreated with 
SPOT-Light Tissue Pretreatment Kit (Life Techologies), following manufacturer’s protocol. 
Probes applied for FISH included LSI ALK, LSI MYC, LSI TP53/CEP17 (Abbott 
Molecular, Ottigne, Belgium or Rome, Italy) and home-brewed bacterial artificial 
chromosome (BAC) clones flanking TRAF1 or BRCA1 genes (Supplemental S2), selected 
from www.ensembl.org, or PRDM1 gene, kindly provided by Dr. Laura Pasqualucci 
(Columbia University, New York, NY, USA). Non-commercial probes were labeled with 
SpectrumOrange- and SpectrumGreen-d-UTP (Abbott Molecular) using random priming. 
FISH images were acquired with a fluorescence microscope equipped with an Axiophot 2 
camera (Carl Zeiss Microscopy, Jena, Germany) and a MetaSystems ISIS imaging system 
(MetaSystems, Altlussheim, Germany). Approximately 100 interphase cells were evaluated 
in each analysis.
RNA-Seq library preparation and Bioinformatics Analysis
RNA-seq was performed as previously described {Palomero, 2014 #1294} Supplementary 
Information). Bionformatics analyses were accomplished using dedicated fusion detection 
tools (Bellerophontes {Abate, 2012 #596}, Defuse {McPherson, 2011 #10377}, 
ChimeraScan {Iyer, 2011 #828} and TxFuse {Singh, 2012 #1061}).
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5′ Race and RT-qPCR
Race {Ma, 2000 #900} and RT-qPCR {Agnelli, 2012 #600} were performed as described. 
The PCR cycling conditions were: 95°C for 5 minutes, followed by 40 cycles at 94°C for 10 
seconds and 60 or 62°C for 30 seconds. Primer sequences are available if requested.
Mice and mice treatment
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were bred within the Molecular 
Biotechnology Center (MBC) Animal Resource, under strict specific and opportunistic 
pathogen free conditions. Animal protocols were reviewed and approved by the Animal 
Committee of the University of Turin. CEP28122 (Cephalon, 100 mg/kg body weight BID) 
were administered by oral gavage. Magnetic resonance imaging and data analysis and 
postprocessing are described in the Supplementary Information.
Tumor grafting and harvesting
Leukemic ALCL cells were obtained from a peripheral blood sample of a refractory ALK+ 
ALCL patient (Supplementary Table S1). For the initial tumorgraft implants, lymphoma 
cells (10–12.5 × 106, 200 μl of Dulbecco’s phosphate buffered saline) were injected 
intravenously (i.v., tail vein), or intraperitoneally (i.p.) or subcutaneously (s.c.) in a total of 
5- to 8-week-old anaesthetized NSG mice (Rompun 0.05μl/g e Zoletil 1.6μg/g i.m.). 
Secondary transplants were performed by injecting 1 × 106 ALCL cells i.v. or alternatively 
implanting s.c. tumor lymphoma fragments (2 to 4, 3×3×1 mm fragments) {Shultz, 2007 
#1059}. Implants’ growth was assessed either by palpation (s.c) and by magnetic resonance 
imaging (MRI). Presence and immunophenotype of human blood circulating cells were 
determined by multicolor flow cytometry {Brusa, 2013 #1258}. Recipient animals were 
checked regularly and sacrificed at early signs of distress. At harvesting, mice were 
sacrificed in a CO2 chamber and tissue grafts were collected for histologic evaluation, re-
grafting, cryopreservation, or snap-freezing in liquid nitrogen.
The log-rank (Mentel-Cox) test was used to compare survival rates among different 
populations. The cumulative probability of overall survival was plotted as a curve according 
to the Kaplan-Meier method.
Antibodies Western Blotting and immune-precipitation assays
The following primary antibodies were used for Western blotting: anti-ALK (Life 
Technology, Monza, IT; mouse 1:2000), TRAF1 (Santa Cruz, rabbit 1:1000) and TRAF2 
(Santa Cruz, Heidelberg DE; mouse 1:1000) anti-Actin Millipore (Merk-Millipore, Milano 
IT; mouse 1:2000), and anti MYC (rabbit 1:1000), antiphospho-STAT3 (rabbit 1:1000), anti 
STAT3-Y705 (rabbit 1:1000), anti SHP2 (rabbit 1:1000), anti SHP2-Y542 (rabbit 1:1000), 
anti ERK1/2-Thr202/Tyr204 (rabbit 1:1000), p50 NFkB (rabbit 1:1000), and p52NFkB 
(rabbit 1:1000) from Cell Signaling Technology (Danvers, MA). Western blotting and 
immunoiprecipaitation studies were performed as previously described {Zamo, 2002 
#5422;Piva, 2006 #1201;Boccalatte, 2009 #639}.
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Cell cultures and viability
Human ALCL cells (TS-SUP-M2, JB-6, Karpass 299, L82 and SU-DHL-1) were cultured 
under standard conditions (37°C in humidified atmosphere, with 5% CO2) in RPMI 1640 
(Sigma-Aldrich, St Luis, MO, USA) and supplemented with 10% fetal calf serum (Lonza, 
Rockland, ME, USA), 2 mM glutamine, 100 U/ml penicillin and 100μg/ml streptomycin 
(Eurobio Biotechnology, Les Ulis, France). Human embryonal kidney cells HEK-293T 
(ATCC, Manassas, VA, USA) were cultivated in supplemented Dulbecco modified Eagle 
medium (DMEM). Cell viability was measured by ATP-lite using Perkin Elmer 
luminometer. Bortezomib, Tripolide, and Carfilzomib (Selleck, Houston, TX, USA), 
CEP28122 (Teva, West Chester, PA, USA) and Crizotinib (Chemitek, Indianapolis, IN, 
USA) were used for in vitro or in vivo studies.
ΔTRAF1-ALK (ΔT/A) and ΔNPM-ALK cassettes were constructed by PCR including the 
first 299 aa of TRAF1 and 100aa of NPM link to a short peptide corresponding to the 
intracytoplasmic region of the ALK gene (first 21 aa of the juxta-membrane region). 
Transfection of HEK-293T cells was performed with Effectene reagent (Qiagen, Valencia, 
CA, USA), according to the manufacturer’s instructions.
Luciferase analysis
Cells were transfected with multiple plasmids in association with pGL3 SOCS3 or IgK–
HIV-kB-driven luciferase reporter and Renilla (1 to 40 ratio) constructs to test the TRAF1-
ALK NFkB mediated transcriptional activity. After transfection (36h), cell lysates were 
prepared from 4×104 cells and dispensed in 96 well/plate, following the manufactorer’s 
instructions. Luciferase expression levels were determined following the recommended 
protocol (Dual-Luciferase Reporter Assay, Promega, Milano, Italy).
Gene expression profiling, processing and data analysis of microarray data
A gene expression profiling (GEP) dataset {Agnelli, 2012 #600} was analyzed as previously 
described {Fu, 2007 #769;Agnelli, 2012 #600}. The neoplastic profiles were derived from 
ALCL (ALK-, no.=24; ALK+, no.=30), PTCL-NOS (no.=74) and angioimmunoblastic T 
cell lymphoma (AITL, no.=41). For the extension/validation analysis we used the total of de 
novo 59 ALCL samples (46 clinically annotated) of the Lymphoma Leukemia Molecular 
Profiling Project and the International Peripheral T-cell Lymphoma Project {Iqbal, 2014 
#1329}. Hierarchical clustering and dendrogram were generated with the GenePattern2.0 
{Reich, 2006 #1214} suite (Pearson correlation distance measure and pairwise average-
linkage clustering method). NFkB related genes were assessed by gene set enrichment 
analysis (GSEA) {Subramanian, 2005 #3408}. We compared the 69 normal T cells and the 
169 neoplastic samples for enrichment of up-regulated NFkB target gene sets. The enriched 
gene sets were established combining the NFkB signatures from the Molecular Signatures 
Database (MsigDB) {Subramanian, 2005 #3408}, the Transcriptional Regulatory Element 
Database {Jiang, 2007 #1220} and NFkB target genes reported in large B-cell lymphoma 
{Feuerhake, 2005 #1213}, breast cancer {Lee, 2011 #1215} and T cells {Nagar, 2010 
#1216}. We randomized the dataset by permuting the gene sets (10000 times) to assess the 
statistical significance. Overall survival significance was assessed by log-rank test. 
Significance associations between categorical data were calculated by Fisher exact test.
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Genome-wide DNA profiling
Fresh and/or cryopreserved primary (ALCL11 [nodal and leukemic], NE433870L 
[diagnostic cervical LN]) and PDT lymphoma samples (ALCL11-PDT T1-1017) underwent 
DNA profiling using the Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, 
CA, USA). Copy Number Variation (CNV) was determined {Rinaldi, 2013 #1221}.
RESULTS
Discovery of a TRAF1-ALK variant chimera
Aggressive forms and rare leukemic presentation of ALK+ ALCL have been reported 
{Savage, 2008 #1044;Schmitz, 2010 #1194;Ferreri, 2012 #1193}. To discover additional 
pathogenetic lesions associated to aggressive ALK+ ALCL cases, we selected a 
chemorefractory patient (ALCL-11) who rapidly evolved to a leukemic phase (Fig. S1A). 
An initial workout on the nodal ALCL lesion showed the presence of back to back 
lymphoma cells, displaying an intense cytoplasmic ALK positivity and a strong nuclear 
immunoreactivity for pSTAT3, p50 and p52 NFkB proteins (Figure 1a). These findings were 
consistent with a variant ALK+ translocation leading to the constitutive activation of JAK-
STAT3 as well as NFkB pathways.
To establish a model representative of ALK variant ALCL, we first cultured the lymphoma 
cells with stromal mesenchymal elements and/or PHA-stimulated PBMC cell conditioned 
media. This strategy was however unsuccessful (data not shown). As alternative approach, 
we implanted fresh leukemic cells into NSG mice. These resulted in the engraftment and 
growth ALCL cells in all mice (100%, Figure 1b) (ALCL-11-PTD) and lymphoma graft 
cells (s.c. tissue fragments or i.v. of single cells from pathological spleens) could be 
successfully propagated in vivo (up to 13 consecutive passages). At autopsy, mice showed a 
disseminated infiltration of the lymphoid organs (i.e. spleen, bone marrow) and different 
parenchymal tissues with minor (kidneys) or extensive architectural effacements (liver) (Fig. 
S2). When we attempted to culture in vitro the ALCL-11 PDT cells (from passage T1 to T8, 
with or without stromal elements and with PHA-conditional media) no sustainable growth 
could be obtained (90% apoptotic cells after 96 h), suggesting that the growth of ALCL-11 
PDT requires additional signals provided by the mouse-host cells.
Next, we performed a FISH to assess and correlate the ALK genomic configuration of 
diagnostic and PDT derived tissues. This analysis demonstrated the presence of the genomic 
rearrangement of the ALK locus, in both primary and PDT cells (Figure 1c). We also 
applied a panel of antibodies (Table S1) on the diagnostic biopsy and in representative tissue 
samples (s.c. tumor masses or spleen), derived from two independent primary engraftment 
lines (Figure 1b). This approach showed that all lymphoma cells had a similar 
immunophenotype (Figure 1d and Fig. S3). No difference were observed from different 
tissue samples (liver, spleen etc.) and/or from animals implanted at different passages and/or 
via alternative routes (subcutaneously or i.v.). Interestingly, variable expression of CD2 and 
CD45 antigens was observed in both primary ALCL and PDT tissues, suggesting a certain 
degree of intraclonal diversity (Figure 1d and S3).
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Since ALCL-11 cells did not display any common variant fusion transcript, we used a next-
generation sequencing RNAseq approach and discovered 29 reads spanning across a 
junction breakpoint corresponding to the TRAF1 and ALK genes. These predicted a novel 
chimeric TRAF1-ALK transcript encoding the first five exons of the TRAF1 gene fused in 
frame to the exons 20–29 of ALK (Figure 2a) {Inghirami, 2012 #1263; Tabbo, 2013 #1093}. 
Validation by Sanger DNA sequencing and RT-PCR confirmed the presence of TRAF1-ALK 
transcripts of primary, relapsed and ALCL11-PDT samples (Figure 2b). These data were 
then validated by additional RNAseq analyses of samples derived from additional PDT (data 
not shown).
To determine the frequency of TRAF1-ALK among variant ALK+ ALCL, a total of 12 
archival cases with cytoplasmic ALK staining were studied by RT-qPCR or 5′-RACE PCR 
on mRNA extracted from either FFPE or frozen tissue samples. One case, corresponding to 
an 11-year old Belgian patient (NE 433870L) displayed TRAF1-ALK mRNA transcripts 
identical to the one detected in ALCL-11 (Figure. S4), suggesting similar breakpoints 
{Feldman, 2013 #16682}. ALK fusions were documented in the remaining cases using a 
break part probe or RT-PCR (ATIC-ALK, TFG-ALK) {Cools, 2002 #695}. To further 
characterize the TRAF1-ALK rearrangement, we designed TRAF1 Break Apart (BA) 
probes. This FISH assay revealed split signals in the interphase lymphoma cells of the 
diagnostic ALCL-11 sample (~50% of the total cells). Conversely, the NE 433870L sample 
showed a normal hybridization pattern. Next we applied two alternative probes covering the 
5′end of TRAF1 (SO-labeled) and the 3′end of ALK (SG-labeled) demonstrating the co-
localization of red/green signals (Figure 2c). Globally, these data document the presence of 
genomic translocations involving the TRAF1 and the ALK loci, occurring with alternative 
modalities.
The TRAF1-ALK fusion leads to the constitutive activation of ALK and NFkB pathways
To define the oncogenic properties of TRAF1-ALK, we initially studied the phosphorylation 
status of the fusion protein and known ALK adaptors. As shown in Figure 2d, untreated 
ALCL-11 cells displayed a phosphorylated ALK band (~ 95kDa), which was substantially 
reduced in samples treated with ALK inhibitors (CEP28122 {Cheng, 2011 #666} and 
Crizotinib). As expected, the loss of ALK signaling led also to the down-regulation of 
pSTAT3 and pShp2 {Tabbo, 2012 #13783}, without substantial changes in cell viability and 
total protein expression (STAT3 and Shp2) within the first hour of treatment (6hr). Next, we 
evaluated the mRNA expression of genes whose expression is known to correlate with ALK-
STAT3 signaling {Piva, 2010 #8623}, demonstrating that anti-ALK treatment led to their 
robust down-regulation (Fig. 2e). Similar data were observed with NPM-ALK positive cells 
lines (Figure S5a,b).
Since TRAF1 interacts with TRAF2, we first demonstrated that TRAF1-ALK could bind 
TRAF2 (Figure 3a,b). Because the intra-cytoplasmic region of ALK contains a TRAF2 
interacting domain {Horie, 2004 #805}, we constructed a truncated form of TRAF1-ALK, 
lacking the TRAF2 ALK docking site (ΔTRAF1-ALK or ΔT/A). Using an antibody 
recognizing the N-terminus of TRAF1, we demonstrated that both WT and TRAF1_ALK 
could co-precipitate TRAF2 (Figure 3c). Knowing that TRAF1-ALK cells express NFkB, 
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p50 and p52 (Figure 3d), we then tested whether ΔTRAF1-ALK could elicit a NFkB 
mediated transcription via a “bona fide” luciferase reporter cassette in cells co-expressing 
CD30 {Horie, 2004 #805}. HEK293T cells were transfected with different ALK cassettes in 
presence of CD30. As previously reported {Horie, 2004 #805}, NPM-ALK but not ELM4-
ALK down-regulated the CD30 mediated NFkB activation (Figure 3e). Moreover, the forced 
expression of ΔTRAF1-ALK but not of ΔNPM-ALK enhanced the CD30-mediated NFkB 
luciferase expression (Figure 3f). To prove that the ΔTRAF1-ALK NFkB signaling requires 
p50 and/or p52, we co-transfected specific p50 and p52 shRNA cassettes, demonstrating 
decreased levels of transcription when they were coexpressed with ΔTRAF1-ALK (Figure 
3f). Lastly, we treated ALCL-11 and/or ALCL-11 PDT cells with a proteasome inhibitor 
(Bortezomib) known to inhibit the NFkB signaling {Hideshima, 2009 #1199}, 
demonstrating a dose- and time-dependent down-regulation of both p50 and p52 protein 
levels (Figure 3g) and known NFkB regulated genes (starting from 12 hrs of incubation, 
Figure 3h). These later changes were associated to decreased cell viability (Figure 3J) and a 
concomitant reduction of intracellular ATP content measured by relative firefly luciferase 
activity (PerkinElmer ATPLite, Figure S6c). Since Bortezomib can inhibit multiple targets, 
we tested alternative proteasome inhibitors demonstrating similar findings in ALCL-11 or 
NPM-ALK cell lines (Figure S6).
Collectively these data demonstrate that TRAF1-ALK can elicit the NFkB pathways, which 
contributes the TRAF1-ALK phenotype.
NFkB is activated in a subset of primary ALK positive and ALK negative ALCL
Since NFkB signaling plays a critical role in regulating stromal-tumor cells responses, we 
undertook a bioinformatics analysis to investigate whether ALCL primary samples displayed 
a unique NFkB signature. We first created a NFkB classifier combing established NFkB 
gene set lists (152 genes, Table S3, see Material and Methods) and tested it in a large cohort 
of ALCL samples and normal purified T cells {Agnelli, 2012 #600}. As expected NFkB 
transcripts from primary ALCL samples were significantly enriched (ES=0.38, NES=1.78, 
p-value < 0.001, FDR < 0.001) compared to purified normal, resting and activated T-cells 
(Figure. S7a,b). The robustness of this gene set classifier was similarly validated in a cohort 
(GSE12195) of diffuse large B-cell lymphoma (DLBCL) samples (Figure S7c) {Compagno, 
2009 #1217}. We then demonstrated that the NFkB classifier could divided the ALCL in 
two different subsets (Figure 4a), which were similarly stratified uisng a mesenchymal 
signature (Figure 4b) {Lenz, 2008 #1225}. Notably, these substs displayed a strong 
correlation (Figure 4b,c). Findings were cross-validated with a second and independent 
ALCL cohort (Figure S7d–e) {Iqbal, 2014 #1329}. More importantly, we proved that the 
ALCL subgroups, which were defined by either the stromal or NFkB signatures, displayed 
unique clinical outcomes and that ALK+ ALCL preferentially enriched among patients with 
a better outcome.
Lastly, when we applied specific antibodies against p50 and p52 in independent set of 98 
ALCL, we found that lymphoma cells (anti-p52: 20/95, 21%; anti-p50: 19/98, 19%) and non 
neoplastic elements (endothelial and stromal cells) were NFkB positive (anti-p52: 87/98, 
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87%; p50: 13/89, 14%, Figure S8), suggesting that both ALCL and host cells can contribute 
to the NFkB signature.
The TRAF1-ALK PDT model bears high-risk genomic lesions
Although many ALK+ ALCL patients reach clinical remission, few refractory {Savage, 
2008 #1044} and rare aggressive forms, carrying translocations or copy number gains of 
MYC {Monaco, 2007 #939}, have been described {Grewal, 2007 #790;Monaco, 2007 
#939;Liang, 2013 #1195;Moritake, 2011 #941}.
To identify genomic aberrations associated to TRAF1-ALK cases, we performed a Copy 
Number Variation (CNV) analysis. ALCL-11 leukemic and T1 and T3 PDT samples showed 
the heterozygous loss of 17p13 region and a concomitant missense mutation within TP53 
gene exon 4 (Figure 5a). Comparison of the DNA profiles of primary, relapsed (post-
therapy) and PDT tissues documented the loss of 20q (100% all samples) and a region 
spanning including the PRDM1/Blimp1 gene (6q, 30% PDTs). Interestingly, PDT samples 
displayed an amplification at 8q (42% of all cells), a region containing the c-MYC gene, a 
finding further confirmed by FISH (Table S4) and by a strong nuclear expression of MYC 
(>90%) (Figure 5b). On the contrary, the NE 433870L TRAF1-ALK ALCL sample showed 
minor CNV changes and a normal genomic configuration of MYC, PRDM1/Blimp1 and 
TP53 genes. This later patient had a remarcable response to chemotherapy and remain in 
clinical remission (Figure 1S), suggesting that the acqusition of multiple genetic defects may 
predict for clinical outcomes.
ALK inhibition can improve the outcome of ALCL-11 PDT mice
Since the management of chemo-refractory ALCL patients remains problematic, we tested 
the therapeutic efficacy of a selected ALK inhibitor in our ALCL-11 PDT model. Mice were 
i.v. tail injected (tumor cells 1×106). Engraftment and disease evolution were assessed by 
enumerating circulating CD30+ cells and by total body magnetic resonance imaging (MRI). 
As a therapeutic scheme, we selected a 14- or 21-day protocol (CEP28122 100mg/kg/bid), 
proven to eradicate disease in NPM-ALK PDT model obtained from a CHOP chemo-
refractory ALCL patient {Cheng, 2011 #666}. As shown in Figure 6 (a and b), untreated 
mice had an increasing number of circulating CD30 cells and enlarging spleens (Figure S9) 
and 62% them succumbed at day 28 (90% after 37 from injection). While 88% of treated 
mice (21 from injection +7 treatment) were alive at day 28 and disease progression was 
controlled in mice treated for consecutive 14 days (Figure 6c). With a longer treatment (21 
days) both spleen size and the percentage of circulating CD30 cells decreased, with an 
improvement of the over survival (p<0.0001). Nevertheless, when the inhibitor was 
withdrawn, circulating lymphoma cells and spleen sizes rose again (Figure 6a,b and Figure 
S10) and mice eventually succumbed with disease (90% at day 60). A similar scenario was 
obtained in a xenograft NPM-ALK cell line model adopting an identical therapeutic 
schedule (14 day treatment, Figure S11).
These data demonstrate that ALK+ chemorefractory leukemic forms can be susceptible to 
anti-ALK kinase inhibitors, remaining addicted to ALK signaling.
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DISCUSSION
We have provided evidence of the pathogenetic role of a novel TRAF1-ALK translocation 
and potential utility of anti-ALK inhibitors in aggressive leukemic forms of ALK+ ALCL. 
The TRAF1-ALK fusion chimera leads to the concomitant activation of ALK and NFkB 
pathways, which contribute to the maintenance of the neoplastic phenotype. Moreover, 
NFkB as well as mesenchymal gene set classifiers can stratify ALCL patients and predict 
clinical outcomes.
It is well established that ALK fusions are powerful oncogenes {Barreca, 2011 #618;Zhang, 
2013 #1260} leading to the constitutive activation of JAK/STAT, PI3K/AKT, Ras/ERK1-2 
and PLC-γ pathways {Barreca, 2011 #618;Tabbo, 2012 #13783}. Moreover, ALK chimera 
can interact with TRAF2 and modulate the CD30-mediate activation of NFkB {Horie, 2004 
#805}. However, the contribution of NFkB signaling in ALCL tumorigenesis remains 
controversial. ALK+ ALCL cell lines have been reported to be devoid of p50 nuclear-
binding activity {Martinez-Delgado, 2005 #1208;Bargou, 1996 #1209}. On the contrary, 
Bcl-3 and p52 are seen in primary ALCL {Mathas, 2005 #1210} and micro-dissected ALCL 
lymphoma cells preferentially express NFkB target genes {Eckerle, 2009 #10607}. Our data 
have confirmed these findings and demonstrated that a gene data set classifier of NFkB can 
reproducibly stratify ALCL, irrespectively of their ALK status. Interestingly, when we 
applied a mesenchymal gene set, known to stratify DLBCL and to predict clinical outcome, 
ALCL were also clustered in two major subgroups, which strongly correlated with those 
defined by the NFkB signature. These data suggest that NFkB signaling may dictate specific 
responses in lymphoma as well as in host cells. The fact that ALCL subgroups have unique 
clinical outcomes is relevant and may provide a novel tool to define poor responders with 
ALK+ ALCL.
Indeed, the pharmacological inhibition of the proteasome degradation known to modulate 
the NFkB pathway could represent a novel therapeutic modality. NFkB inhibitors could 
target either the lymphoma cells (TRAF1-ALK) or the host elements with a modality 
previously reported in other settings {Hiruma, 2009 #1261;Lwin, 2007 #1262}. Targeting 
the microeviroment has been recently proposed as analogous strategy in ALCL patients 
{Laimer, 2012 #872}.
Since many ALK- and a sizable subset of ALK+ALCL (20–30%) fail to reach clinical 
remission and prolong disease free survival {Savage, 2008 #1044;Grewal, 2007 #1181}, 
predicting biomarkers are highly desirable. The loss of TP53, PRDM1/Blimp1 {Boi, 2013 
#1207} and TP63 {Vasmatzis, 2012 #1132} and deregulated expression of MYC {Monaco, 
2007 #939} might pinpoint at diagnosis refractory/relapse or even aggressive forms of 
ALCL. In our PDT model, the emergency of subclones carrying defects of PRDM1/Blimp1 
and MYC support the hypothesis that these lesions may have a relevant pathogenetic role 
and might occur as additional event along tumorigenesis contributing to more aggressive 
phenotype. A scenario previously described in acute lymphoblastic/leukemic PDT models 
{Clappier, 2011 #685}.
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We have described the properties of a novel TRAF1-ALK fusion showing the unique 
contribution of its N-terminal TRAF1 region and demonstrated by ALK and NFkB can 
contribute to the neoplastic phenotype. The generation of PDT should represent a powerful 
approach to design more efficacious therapies in individual patients, particularly in the 
setting of relapses or refractoriness.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
GI is supported by the Italian Association for Cancer Research (AIRC) Special Program in Clinical Molecular 
Oncology, Milan (5x1000 No. 10007); Regione Piemonte (ONCOPROT, CIPE 25/2005); ImmOnc (Innovative 
approaches to boost the immune responses, Programma Operativo Regionale, Piattaforme Innovative BIO F.E.S.R. 
2007/13, Asse 1 ‘Ricerca e innovazione’ della LR 34/2004) and the Oncology Program of Compagnia di San Paolo, 
Torino. SP and BF by the Italian Association for Cancer Research (AIRC) Special Program in Clinical Molecular 
Oncology, Milan (5x1000 No. 10007); RR by Partnership for Cure, NIH 1 P50 MH094267-01, NIH 1 U54 
CA121852-05, NIH 1R01CA164152-01. FB is sponsored by the Oncosuisse KLS-02403-02-2009 (Bern, 
Switzerland); Anna Lisa Stiftung (Ascona, Switzerland); Nelia and Amadeo Barletta Foundation (Lausanne, 
Switzerland); RP by Rete Oncologica del Piemonte e della Valle d’Aosta. LDS by National Institutes of Health 
(USA) grant CA034196. M.B. and M.T., I.L., F.T. F.dG., R.C and L.B. are enrolled in the PhD program 
(Pharmaceutical Sciences, University of Geneva, Switzerland and Molecular Medicine, University of Torino, 
respectively). We thank Drs. Vigliani C, Fioravanti A., and Mossino M. for their technical support and to Dr Casano 
J. for the constructive revision of the manuscript.
References
1. Falini B, Martelli MP. Anaplastic large cell lymphoma: changes in the World Health Organization 
classification and perspectives for targeted therapy. Haematologica. 2009; 94(7):897–900. [PubMed: 
19570751] 
2. Swerdlow, SHCE.; Harris, NL.; Jaffe, ES.; Pileri, SA.; Stein, H.; Thiele, J., et al. WHO 
classification of tumors of haemotolopoietic and lymphoid tissues. 4. Stylus Publishing, LLC; 
Sterling, VA: 2008. 
3. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell 
lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral 
T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell 
Lymphoma Project. Blood. 2008; 111(12):5496–5504. [PubMed: 18385450] 
4. Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis 
of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in 
studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010; 116(18):
3418–3425. [PubMed: 20660290] 
5. Monaco S, Tsao L, Murty VV, Nandula SV, Donovan V, Oesterheld J, et al. Pediatric ALK+ 
anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement 
terminating in a leukemic phase. Am J Hematol. 2007; 82(1):59–64. [PubMed: 16955462] 
6. Liang X, Branchford B, Greffe B, McGavran L, Carstens B, Meltesen L, et al. Dual ALK and MYC 
rearrangements leading to an aggressive variant of anaplastic large cell lymphoma. J Pediatr Oncol. 
2013; 35(5):e209–213.
7. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-positive. Crit Rev 
Oncology Hematol. 2012; 83(2):293–302.
8. Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, et al. Anaplastic lymphoma 
kinase in human cancer. J Mol Endocrinol. 2011; 47(1):R11–23. [PubMed: 21502284] 
9. Miranda C, Roccato E, Raho G, Pagliardini S, Pierotti MA, Greco A. The TFG protein, involved in 
oncogenic rearrangements, interacts with TANK and NEMO, two proteins involved in the NF-
kappaB pathway. J Cell Physiol. 2006; 208(1):154–160. [PubMed: 16547966] 
Abate et al. Page 12
Leukemia. Author manuscript; available in PMC 2016 May 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
10. Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbo F, et al. PRDM1/BLIMP1 is commonly 
inactivated in anaplastic large T-cell lymphoma. Blood. 2013; 122(15):2683–2693. [PubMed: 
24004669] 
11. Grewal JS, Smith LB, Winegarden JD 3rd, Krauss JC, Tworek JA, Schnitzer B. Highly aggressive 
ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: 
a report of three cases and a review of the literature. Ann Hematol. 2007; 86(7):499–508. 
[PubMed: 17396261] 
12. Moritake H, Shimonodan H, Marutsuka K, Kamimura S, Kojima H, Nunoi H. C-MYC 
rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive 
anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C-MYC. Am J 
Hematol. 2011; 86(1):75–78. [PubMed: 21080342] 
13. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system 
investigation: progress, promise and challenges. Nat Rev Immunol. 2012; 12(11):786–798. 
[PubMed: 23059428] 
14. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour 
formation by single human melanoma cells. Nature. 2008; 456(7222):593–598. [PubMed: 
19052619] 
15. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour 
xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9(6):338–350. 
[PubMed: 22508028] 
16. Garber K. From human to mouse and back: ‘tumorgraft’ models surge in popularity. J Natl Cancer 
Inst. 2009; 101(1):6–8. [PubMed: 19116380] 
17. Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A, et al. 
Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse 
model of human acute lymphoblastic leukemia. Leukemia. 2012; 26(7):1517–1526. [PubMed: 
22307227] 
18. Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W, et al. CEP-28122, a highly potent and 
selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in 
experimental models of human cancers. Mol Cancer Ther. 2012; 11(3):670–679. [PubMed: 
22203728] 
19. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An in 
vivo platform for translational drug development in pancreatic cancer. Clinical Cancer Res. 2006; 
12(15):4652–4661. [PubMed: 16899615] 
20. Feldman AL, Vasmatzis G, Asmann YW, Davila J, Middha S, Eckloff BW, et al. Novel TRAF1-
ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. Genes 
Chromosomes Cancer. 2013; 52(11):1097–1102. [PubMed: 23999969] 
21. Tabbo F, Barreca A, Machioriatti R, Messana K, Landra I, Abate F, et al. Humanized NOD/Scid/
IL2g-/- tumor grafts recapitulate primary anaplastic large cell lymphoma. AACR Annual Meeting. 
2013 abstract 3853. 
22. Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, et al. Gene expression profiling 
uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within 
peripheral T-cell neoplasms. J Clin Oncol. 2010; 28(9):1583–1590. [PubMed: 20159827] 
23. Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, et al. 
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell 
lymphomas. Nat Genet. 2014; 46(2):166–170. [PubMed: 24413734] 
24. Abate F, Acquaviva A, Paciello G, Foti C, Ficarra E, Ferrarini A, et al. Bellerophontes: an RNA-
Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model. 
Bioinformatics. 2012; 28(16):2114–2121. [PubMed: 22711792] 
25. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, et al. deFuse: an algorithm 
for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biology. 2011; 7(5):e1001138.
26. Iyer MK, Chinnaiyan AM, Maher CA. ChimeraScan: a tool for identifying chimeric transcription 
in sequencing data. Bioinformatics. 2011; 27(20):2903–2904. [PubMed: 21840877] 
Abate et al. Page 13
Leukemia. Author manuscript; available in PMC 2016 May 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
27. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR 
and TACC genes in human glioblastoma. Science. 2012; 337(6099):1231–1235. [PubMed: 
22837387] 
28. Ma Z, Cools J, Marynen P, Cui X, Siebert R, Gesk S, et al. Inv(2)(p23q35) in anaplastic large-cell 
lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by 
fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood. 2000; 95(6):2144–
2149. [PubMed: 10706887] 
29. Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E, et al. Identification of a 3-gene 
model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell 
lymphoma. Blood. 2012; 120(6):1274–1281. [PubMed: 22740451] 
30. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev 
Immunology. 2007; 7(2):118–130. [PubMed: 17259968] 
31. Brusa D, Serra S, Coscia M, Rossi D, D’Arena G, Laurenti L, et al. The PD-1/PD-L1 axis 
contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013; 98(6):
953–963. [PubMed: 23300177] 
32. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, et al. Anaplastic lymphoma kinase (ALK) 
activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002; 21(7):1038–
1047. [PubMed: 11850821] 
33. Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, et al. Ablation of oncogenic 
ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood. 2006; 107(2):
689–697. [PubMed: 16189272] 
34. Boccalatte FE, Voena C, Riganti C, Bosia A, D’Amico L, Riera L, et al. The enzymatic activity of 
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is 
enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. 
Blood. 2009; 113(12):2776–2790. [PubMed: 18845790] 
35. Fu L, Medico E. FLAME, a novel fuzzy clustering method for the analysis of DNA microarray 
data. BMC Bioinformatics. 2007; 8:3. [PubMed: 17204155] 
36. Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression 
signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 
2014; 123(19):2915–2923. [PubMed: 24632715] 
37. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet. 2006; 
38(5):500–501. [PubMed: 16642009] 
38. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-wide expression 
profiles. Proc Nat Acad Sci USA. 2005; 102(43):15545–15550. [PubMed: 16199517] 
39. Jiang C, Xuan Z, Zhao F, Zhang MQ. TRED: a transcriptional regulatory element database, new 
entries and other development. Nucleic Acids Res. 2007; 35(Database issue):D137–140. [PubMed: 
17202159] 
40. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, et al. NFkappaB activity, 
function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse 
large B-cell lymphoma subtypes. Blood. 2005; 106(4):1392–1399. [PubMed: 15870177] 
41. Lee ST, Li Z, Wu Z, Aau M, Guan P, Karuturi RK, et al. Context-specific regulation of NF-kappaB 
target gene expression by EZH2 in breast cancers. Mol Cell. 2011; 43(5):798–810. [PubMed: 
21884980] 
42. Nagar M, Jacob-Hirsch J, Vernitsky H, Berkun Y, Ben-Horin S, Amariglio N, et al. TNF activates a 
NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their 
suppressive function. J Immunol. 2010; 184(7):3570–3581. [PubMed: 20181891] 
43. Rinaldi A, Kwee I, Young KH, Zucca E, Gaidano G, Forconi F, et al. Genome-wide high resolution 
DNA profiling of hairy cell leukaemia. Br J Haematol. 2013; 162(4):566–569. [PubMed: 
23692203] 
44. Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B, et al. Identification of novel 
fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and 
inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2002 Aug; 34(4):354–362. 
[PubMed: 12112524] 
Abate et al. Page 14
Leukemia. Author manuscript; available in PMC 2016 May 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
45. Tabbo F, Barreca A, Piva R, Inghirami G. European TCLSG. ALK Signaling and Target Therapy in 
Anaplastic Large Cell Lymphoma. Front Oncol. 2012; 2:41. [PubMed: 22649787] 
46. Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K, et al. The NPM-ALK oncoprotein 
abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell 
lymphoma. Cancer cell. 2004; 5(4):353–364. [PubMed: 15093542] 
47. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, et al. Bortezomib induces 
canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009; 114(5):1046–
1052. [PubMed: 19436050] 
48. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of 
multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009; 
459(7247):717–721. [PubMed: 19412164] 
49. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-
cell lymphomas. N Eng J Med. 2008; 359(22):2313–2323.
50. Zhang Q, Wei F, Wang HY, Liu X, Roy D, Xiong QB, et al. The potent oncogene NPM-ALK 
mediates malignant transformation of normal human CD4(+) T lymphocytes. Am J Pathol. 2013; 
183(6):1971–1980. [PubMed: 24404580] 
51. Martinez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J, et al. 
Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. 
Leukemia. 2005; 19(12):2254–2263. [PubMed: 16270046] 
52. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, et al. High-level 
nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. 
Blood. 1996; 87(10):4340–4347. [PubMed: 8639794] 
53. Mathas S, Johrens K, Joos S, Lietz A, Hummel F, Janz M, et al. Elevated NF-kappaB p50 complex 
formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-
cell lymphomas. Blood. 2005; 106(13):4287–4293. [PubMed: 16123212] 
54. Eckerle S, Brune V, Doring C, Tiacci E, Bohle V, Sundstrom C, et al. Gene expression profiling of 
isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, 
pathogenesis and relation to Hodgkin lymphoma. Leukemia. 2009; 23(11):2129–2138. [PubMed: 
19657361] 
55. Hiruma Y, Honjo T, Jelinek DF, Windle JJ, Shin J, Roodman GD, et al. Increased signaling through 
p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. 
Blood. 2009; 113(20):4894–4902. [PubMed: 19282458] 
56. Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, et al. Bone marrow 
stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins 
associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin’s lymphoma cells. 
Leukemia. 2007; 21(7):1521–1531. [PubMed: 17476277] 
57. Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, et al. PDGFR blockade is 
a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med. 2012; 18(11):1699–
1704. [PubMed: 23064464] 
58. Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, et al. Genome-wide 
analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in 
peripheral T-cell lymphomas. Blood. 2012; 120(11):2280–2289. [PubMed: 22855598] 
59. Clappier E, Gerby B, Sigaux F, Delord M, Touzri F, Hernandez L, et al. Clonal selection in 
xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at 
relapse. J Exp Med. 2011; 208(4):653–661. [PubMed: 21464223] 
Abate et al. Page 15
Leukemia. Author manuscript; available in PMC 2016 May 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig 1. The ALCL-11 Patient Derived Tumorgraft line mimics its corresponding primary tissues 
sample
(A) Immunohistochemistry stains performed on primary diagnostic sample (ALCL-11) show 
a strong ALK cytoplasmic staining with an antibody (D5F3, Cell Signaling Technology) 
specific for an intracytoplasmic peptide of the human ALK gene (x 400). Tissue sections 
stained with specific antibody against human phospoSTAT3 (pSTAT3, x100), p50 and p52 
demonstrate a variable number lymphoma cells with nuclear positivity (x400). These 
analyses were performed on the diagnostic/primary tissue sample of the ALCL-11 patient.
(B) PDT engraftment and serial tumor propagation in NSG mice. Two distinct engraftments 
are depicted with their serial passages. Intersecting lines define the relationship among 
different tumors. Yellow boxes show mice the lymphoma tissue samples used for IHC stains.
(C) FISH analysis was performed on the primary tissue and in a representative PDT 
(ALCL-11 PDT1-2152) sample using a commercial kit and break apart set recognizing the 
2p23 regions (Abbott Molecular/Vysis LSI ALK Break Apart FISH Probe Kit).
(D) Immunohistochemical stains were performed with specific antibodies recognizing T-cell 
associated and/or restricted antigens on the primary and serial PDT tissue samples (see Table 
S1). Percentage of positive cells and intensity of staining are indicated in the above diagram. 
Broken patterns indicate the presence of heterogeneous staining patterns.
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Figure 2. ALCL11 harbors the novel TRAF1-ALK fusion protein and leads to the constitutive 
activation of ALK signaling pathway
(A) TRAF1–ALK gene fusion was defined by RNAseq (with 29 split reads overlapping 
junction breakpoint across TRAF1 and ALK). The genomic coordinates are shown. TRAF1 
exon 5 and ALK exon 20 reading frames were conserved (central panel). The TRAF1-ALK 
chimera includes the TRAF1 and Coiled-coil domains, fused to the ALK intra-cytoplasmic 
region (lower panel).
(B) TRAF1-ALK fusion transcripts are detected in primary, leukemic and ALCL11-PDT 
samples by RT-PCR. ALK + (SUP-M2) and ALK- (MAC1) lines were used as controls. 
Negative controls correspond to samples lacking cDNA templates.
(C) TRAF1 BA assay (see supplementary T2S) was designed to validate molecular results 
by FISH. Case NE 433870L showed a normal hybridization pattern of TRAF1 BA in all 
analyzed interphase cells. To test if the TRAF1-ALK fusion might occur by an insertion of 
the 3′ALK within the TRAF1 locus in case 2, we applied probes covering the 5′end of 
TRAF1 (SO-labeled) and the 3′end of ALK (SG-labeled) (Upper right panel). Examination 
with MYC, TP53 and BLIMP1 of NE 433870L diagnostic tissue showed a normal 
hybridization pattern for all three probes (data not shown). ALCL-11 revealed split TRAF1 
BA signals in approximately 50% of interphase cells (Lower panel);
(D) TRAF1-ALK signaling is inhibited by anti-ALK inhibitors. PDT cells (PDT-3-2330) 
and SUP-M2 as control were treated in vitro (6hr, Crizotinib or CEP28122, 200nM). Total 
cell lysates were immune-blotted with the indicated antibodies.
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(E) Panel shows the normalized levels of mRNA expression of STAT3 and representative 
STAT3-responsive genes in untreated or (anti-ALK) CEP28122 treated ALCL-11 leukemic 
cells (200nM, 6hr treatment). Expression levels were determined using a qRT-PCR approach 
as previously described {Piva, 2010 #8623;Agnelli, 2012 #599}. Data are depicted as 
2^ddCt.5. Expression levels GAPDH of untreated (reference value) and CEP28122 treated 
cells are reported.
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Figure 3. TRAF1-ALK leads to the constitutive activation of NFkB transcription members
(A–B) Lysates from a representative NPM-ALK cell line (SUP-M2 and Karpas 299) and 
leukemic ALCL-11 cells were immune-precipitated with an anti-ALK (Panel A) and anti-
TRAF1 (B) antibodies. Immuno-complexes were resolved and then blotted with the 
indicated antibodies. Immuno-precipitates in presence of mouse serum are depicted as well 
(Beads). TL: Total Lysates, SN: Supernatant and IP Immune Precipitation. Protein molecular 
weights are shown. (C) Lysates from HEK293T cells, transfected with the full length 
TRAF1-ALK and ΔTRAF1-ALK, were immuno-precipitated with an anti-TRAF2 
antibodies. Immuno-complexes were resolved and blotted with anti-TRAF1 antibodies. The 
expression of the corresponding proteins prior the immune-precipitation is shown (Total 
lysate) Predicted protein molecular weights are indicated.
(D) ALCL-11 cells show constitutive activation of the NFkB pathway. Primary ALCL-11 
cells were immune-blotted with antibodies recognizing p105/p50 and p100/p52 NFkB. 
NPM-ALK+ ALCL cell lines were used as control.
(E) Luciferase Expression of transfected HEK-293T cells. Cells were transfected with the 
indicated cassettes expressing CD30, NFkB-ROS, CD30+NPM-ALK (active form), 
CD30+K210R NPM_ALK (inactive form) and CD30+ EML4-ALK.
(F) Knock-down of p50 or p52 impairs the NFkB mediated luciferase expression via CD30 
signaling. HEK-293T cells were transfected with the indicated cassettes in presence of a 
CD30 expression vector.
(G) Protein expression of untreated and treated (Bortezomib 5nM/10nM) ALCL-11-PDTs 
was determined at 36 hr by Western Blotting with specific antibodies.
(H) Panel shows the normalized levels of mRNA expression of NFkB-regulated genes in 
untreated (control) or Bortezomib treated ALCL-11 leukemic cells (10nM, at 6 and 12 hr of 
culture). Expression levels were determined using a qRT-PCR approach as previously 
described {Piva, 2010 #8623;Agnelli, 2012 #599}. Data are depicted as 2^ddCt. Expression 
levels GAPDH of 6 hr treated (reference value) and 12 hr treated cells are reported.
(J) ALCL-11 cells are sensitive to Bortezomib. Primary cells (1×105/ml) were treated with 
increasing dose of the drug, overtime. Data have been normalized to control DMSO treated 
cells. DMSO viability decreased over time with a 30–40% spontaneous cell death at 36hrs.
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Figure 4. 
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Figure 5. GSEA identifies distinct subsets of ALCL among PTCL and normal samples
(A and B) Unsupervised hierarchical clustering (NFKB and Mesenchymal1 gene set) 
classifies ALCL in two distinct groups, respectively NKFBclus1/NKFBclus1 and MesClus1/
MesClus2, (Pearson correlation distance measure, pairwise average-linkage clustering) with 
a significant association between the two groups (pvalue < 0.0001, Fisher exact test)
(C and D) Overall survival (OS) analysis of the two molecularly defined clusters for both 
NFKB and Mesenchymal gene set (M1=Mch1, M2=Mch2, NK1=NFKB1, NK2=NFKB2, 
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see figure S7) in an independent cohort of 46 ALCL. Tables show a significant correlation 
between the NFKB/Mesenchymal groups and the ALK status in ALCL.
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Figure 6. CGH analysis of primary and PDT ALCL-11 show the emergency of subclonal 
population lacking TP53 and MYC amplification
(A) SNP-array plots of ALCL11-PDT identified a los at 17p13.1 (TP53) and 6q21 
(PRDM1) and a gene amplification at 8q24 (MYC). X-axis: chromosome localization and 
physical mapping; Y-axis: signal indicating copy number status at each locus. DNA 
sequencing of normal and pathological DNA derived form Patient ALCL-11.
(B) IHC stains of primary and PDTs (ALCL-11-PDT-T4) tissue samples by an anti-MYC 
(Y69, Epitomics, Burlingame, CA) and Ki-67 (MIB-1, Dako Italia S.p.A, Italy) Mab. 
Original magnification x400.
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Figure 7. Single therapy with anti-ALK inhibitor leads to a partial response of ALCL1-11-PDT 
mice
(A) ALCL-11 PDT2-6 (injected with 1×106 lymphoma cells, i.v) were analyzed using a 
dedicated MRI unit to determine the volume of the spleen as a surrogate of lymphoma/
leukemia burden. Mice were treated with CEP28122, 100mg/kg/BID starting day 21th from 
the i.v. inoculum and scanned a different intervals (7, 14 or 21 days). A cohort of treated 
mice (14 days) were then released and followed overtime (7 or 14 days off). Numbers of 
mice are indicated.
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(B) ALCL-11 PDT2-6 (injected with 1×106 lymphoma cells, i.v) were bled and blood 
circulating human CD45+CD30+ cells were determined by flow cytometry. Mice were 
treated with CEP28122, 100mg/kg/BID as indicate above. Numbers of mice are indicated.
(C) Effect of CEP28122 treatment in ALCL-11 PDT. Waterfall plot of mice injected with 
1×106 ALCL-11 cells (i.v. day 21, grey bars) and CEP28122 response (day 21+14, back 
bars) after two weeks of treatment, compared with tumor volume at baseline (day 21), in 24 
cases.
(D) Overall survival of ALCL-11-PDT treated with anti-ALK (CEP28122). Mice were 
randomized and treated as indicated with 100mg/kg/BID CEP28122 as indicated.
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